Security and reliability of CUSTOMBONE cranioplasties: A prospective multicentric study.


Journal

Neuro-Chirurgie
ISSN: 1773-0619
Titre abrégé: Neurochirurgie
Pays: France
ID NLM: 0401057

Informations de publication

Date de publication:
Jul 2021
Historique:
received: 01 06 2020
revised: 07 02 2021
accepted: 13 02 2021
pubmed: 6 3 2021
medline: 14 7 2021
entrez: 5 3 2021
Statut: ppublish

Résumé

Repairing bone defects generated by craniectomy is a major therapeutic challenge in terms of bone consolidation as well as functional and cognitive recovery. Furthermore, these surgical procedures are often grafted with complications such as infections, breaches, displacements and rejections leading to failure and thus explantation of the prosthesis. To evaluate cumulative explantation and infection rates following the implantation of a tailored cranioplasty CUSTOMBONE prosthesis made of porous hydroxyapatite. One hundred and ten consecutive patients requiring cranial reconstruction for a bone defect were prospectively included in a multicenter study constituted of 21 centres between December 2012 and July 2014. Follow-up lasted 2 years. Mean age of patients included in the study was 42±15 years old (y.o), composed mainly by men (57.27%). Explantations of the CUSTOMBONE prosthesis were performed in 13/110 (11.8%) patients, significantly due to infections: 9/13 (69.2%) (p<0.0001), with 2 (15.4%) implant fracture, 1 (7.7%) skin defect and 1 (7.7%) following the mobilization of the implant. Cumulative explantation rates were successively 4.6% (SD 2.0), 7.4% (SD 2.5), 9.4% (SD 2.8) and 11.8% (SD 2.9%) at 2, 6, 12 and 24 months. Infections were identified in 16/110 (14.5%): 8/16 (50%) superficial and 8/16 (50%) deep. None of the following elements, whether demographic characteristics, indications, size, location of the implant, redo surgery, co-morbidities or medical history, were statistically identified as risk factors for prosthesis explantation or infection. Our study provides relevant clinical evidence on the performance and safety of CUSTOMBONE prosthesis in cranial procedures. Complications that are difficulty incompressible mainly occur during the first 6 months, but can appear at a later stage (>1 year). Thus assiduous, regular and long-term surveillances are necessary.

Sections du résumé

BACKGROUND BACKGROUND
Repairing bone defects generated by craniectomy is a major therapeutic challenge in terms of bone consolidation as well as functional and cognitive recovery. Furthermore, these surgical procedures are often grafted with complications such as infections, breaches, displacements and rejections leading to failure and thus explantation of the prosthesis.
OBJECTIVE OBJECTIVE
To evaluate cumulative explantation and infection rates following the implantation of a tailored cranioplasty CUSTOMBONE prosthesis made of porous hydroxyapatite. One hundred and ten consecutive patients requiring cranial reconstruction for a bone defect were prospectively included in a multicenter study constituted of 21 centres between December 2012 and July 2014. Follow-up lasted 2 years.
RESULTS RESULTS
Mean age of patients included in the study was 42±15 years old (y.o), composed mainly by men (57.27%). Explantations of the CUSTOMBONE prosthesis were performed in 13/110 (11.8%) patients, significantly due to infections: 9/13 (69.2%) (p<0.0001), with 2 (15.4%) implant fracture, 1 (7.7%) skin defect and 1 (7.7%) following the mobilization of the implant. Cumulative explantation rates were successively 4.6% (SD 2.0), 7.4% (SD 2.5), 9.4% (SD 2.8) and 11.8% (SD 2.9%) at 2, 6, 12 and 24 months. Infections were identified in 16/110 (14.5%): 8/16 (50%) superficial and 8/16 (50%) deep. None of the following elements, whether demographic characteristics, indications, size, location of the implant, redo surgery, co-morbidities or medical history, were statistically identified as risk factors for prosthesis explantation or infection.
CONCLUSION CONCLUSIONS
Our study provides relevant clinical evidence on the performance and safety of CUSTOMBONE prosthesis in cranial procedures. Complications that are difficulty incompressible mainly occur during the first 6 months, but can appear at a later stage (>1 year). Thus assiduous, regular and long-term surveillances are necessary.

Identifiants

pubmed: 33667533
pii: S0028-3770(21)00046-1
doi: 10.1016/j.neuchi.2021.02.007
pii:
doi:

Substances chimiques

Durapatite 91D9GV0Z28

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

301-309

Informations de copyright

Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Auteurs

A Amelot (A)

Neurosurgery department, Hôpital de Bretonneau, Tours, France. Electronic address: aymmed@hotmail.fr.

A Nataloni (A)

Clinical research department, Finceramica Faenza S.p.A, Ravenna, Italy.

P François (P)

Neurosurgery department, Hôpital de Bretonneau, Tours, France.

A-R Cook (AR)

Neurosurgery department, Hôpital de Bretonneau, Tours, France.

J-P Lejeune (JP)

Neurosurgery department, CHRU Lille, Lille, France.

M Baroncini (M)

Neurosurgery department, CHRU Lille, Lille, France.

P-L Hénaux (PL)

Neurosurgery department, CHU Rennes, Rennes, France.

P Toussaint (P)

Neurosurgery department, CHU Amiens, Amiens, France.

J Peltier (J)

Neurosurgery department, CHU Amiens, Amiens, France.

K Buffenoir (K)

Neurosurgery department, CHU Nantes, Nantes, France.

O Hamel (O)

Neurosurgery department, CHU Nantes, Nantes, France.

P Dam Hieu (PD)

Neurosurgery department, CHU Brest, Brest, France.

S Chibbaro (S)

Neurosurgery department, CHU Strasbourg, Strasbourg, France.

P Kehrli (P)

Neurosurgery department, CHU Angers, Angers, France.

M A Lahlou (MA)

Neurosurgery department, CHU Strasbourg, Strasbourg, France.

P Menei (P)

Neurosurgery department, CHU Angers, Angers, France.

M Lonjon (M)

Neurosurgery department, CHU Nice, Nice, France.

C Mottolese (C)

Neurosurgery department, CHU Neurologique Lyon, Lyon, France.

P Peruzzi (P)

Neurosurgery department, CHU Maison Blanche, Reims, France.

K Mahla (K)

Neurosurgery department, clinique du Tonkin, Villeurbanne, France.

D Scarvada (D)

Neurosurgery department, CHU La Timone, Marseille, France.

C Le Guerinel (C)

Neurosurgery department, CHU Henri Mondor, Creteil, France.

P Caillaud (P)

Neurosurgery department, CH de la Côte Basque, Bayonne, France.

C Nuti (C)

Neurosurgery department, CHU St Etienne, St Etienne, France.

B Pommier (B)

Neurosurgery department, CHU St Etienne, St Etienne, France.

T Faillot (T)

Neurosurgery department, CHU Hôpital Beaujon, Clichy, France.

G Iakovlev (G)

Neurosurgery department, CHU Hôpital Beaujon, Clichy, France.

S Goutagny (S)

Neurosurgery department, CHU Hôpital Beaujon, Clichy, France.

N Lonjon (N)

Neurosurgery department, CHU Gui de Chauliac, Montpellier, France.

P Cornu (P)

Neurosurgery department, CHU Pitié-Salpêtrière, Paris, France.

P Bousquet (P)

Neurosurgery department, Clinique des Cèdres, Cornebarrieu, France.

P Sabatier (P)

Neurosurgery department, Clinique des Cèdres, Cornebarrieu, France.

B Debono (B)

Neurosurgery department, Clinique des Cèdres, Cornebarrieu, France.

J-P Lescure (JP)

Neurosurgery department, Clinique des Cèdres, Cornebarrieu, France.

E Vicaut (E)

Clinical research unit (URC), Hôpital de Lariboisière, APHP, Paris, France.

S Froelich (S)

Neurosurgery department, Hôpital de Lariboisière, APHP, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH